Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: Estimation via a Sampling-Based approach

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Geng, Elvin H ^a,e   Glidden, David V ^a,e   Bwana, Mwebesa Bosco ^b,e   Musinguzi, Nicolas ^b,e   Emenyonu, Nneka ^b,d,e   Muyindike, Winnie ^b,e   Christopoulos, Katerina A ^a   Neilands, Torsten B ^a   Yiannoutsos, Constantin T ^c,e   Deeks, Steven G ^a   Bangsberg, David R ^d,e   Martin, Jeffrey N ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^c INDIANA UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e East Africa International Epidemiologic Databases to Evaluate AIDS   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HEALTH EDUCATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; SAMPLING; CONFIDENCE INTERVAL; EPIDEMIOLOGY; FOLLOW UP; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; UGANDA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONFIDENCE INTERVALS; DELIVERY OF HEALTH CARE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; SAMPLING STUDIES; UGANDA;

EID: 79960754251     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021797     Document Type: Article

References (22)

1. Navario P, (2009) PEPFAR's biggest success is also its largest liability. Lancet 374: 184-185.
2. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
3. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20: 41-48.
4. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 559-567.
5. van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, et al. (2005) Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 10: 464-470.
6. Losina E, Toure H, Uhler LM, Anglaret X, Paltiel AD, et al. (2009) Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d'Ivoire appraisal. PLoS Med 6: e1000173.
7. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.
8. (2009) Uganda Districts Information Handbook: Expanded Edition 2007-2009 Kampala Fountain Publishers.
9. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, et al. (2007) Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21: 713-719.
10. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935.
11. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, et al. (2008) Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 47: 1556-1561.
12. Makadzange A, Ndhlovu C, Takarinda K, et al. E. Early vs Delayed ART in the Treatment of Cryptococcal Meningitis in Africa.; 2009; Montreal, Canada.
13. Kaplan EL, Meier P, (1958) Nonparametric estimation from incomplete observations. J Amer Statist Assn 53: 457-481.
14. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, et al. (1978) The analysis of failure times in the presence of competing risks. Biometrics 34: 541-554.
15. Coviello V, Boggess M, (2004) Cumulative incidence estimation in the presence of competing risks. The Stata Journal 4.
16. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, et al. (2004) A note on competing risks in survival data analysis. Br J Cancer 91: 1229-1235.
17. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN, (2008) Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 300: 506-507.
18. Frangakis CE, Rubin DB, (2001) Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring. Biometrics 57: 333-342.
19. (2009) International Center for AIDS Care and Treatment Programs (ICAP) E News October 2009. ICAP News. Available: http://www.columbia-icap.org/news/icapnews/OctoberENews.html. Accessed 2010 Feb 23.
20. Bedelu M, Ford N, Hilderbrand K, Reuter H, (2007) Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 196 (Suppl 3): S464-468.
21. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, et al. (2008) Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 47: 421-424.
22. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.